Altimmune, Inc. (ALT)
5.35
-0.08
(-1.38%)
USD |
NASDAQ |
Dec 11, 16:00
5.35
0.00 (0.00%)
After-Hours: 20:00
Altimmune Cash from Investing (Quarterly): -149.32M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Viking Therapeutics, Inc. | 160.02M |
| Eli Lilly & Co. | -2.983B |
| Pfizer Inc. | -2.43B |
| Terns Pharmaceuticals, Inc. | 24.50M |
| Rhythm Pharmaceuticals, Inc. | -246.35M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -11.90M |
| Cash from Financing (Quarterly) | 39.35M |
| Free Cash Flow | -66.66M |
| Free Cash Flow Per Share (Quarterly) | -0.133 |
| Free Cash Flow to Equity (Quarterly) | -11.95M |
| Free Cash Flow to Firm (Quarterly) | -11.40M |
| Free Cash Flow Yield | -15.69% |